Data Disclosure Survey
Data Disclosure Survey
MeTA baseline component 1b
Developed by: World Health Organization Collaborating Center on Pharmaceutical Policy at Harvard University World Health Organization (WHO) / MeTA
Objective: To assess and describe the current disclosure status of information in the core areas of:
- medicines registration and quality assurance
- the availability of medicines
- the price of medicines
- the policies and practices concerning the promotion of medicines
Output: A standardised report that presents the available disclosed information covering policies – the laws and regulations that are in place; practices – suggested procedures to follow and actual practices; and results – achievements in the core areas listed above.
Additional information: This tool enables national stakeholders to prioritise activities and facilitates progressive disclosure over time. It creates a baseline against which changes in transparency and disclosure can be measured. It also facilitates multi-stakeholder engagement since it requires that the stakeholders disclose relevant information they and the institutions they represent hold. This information is then cross validated by the multi-stakeholder group.
Process and resources:
- This tool does not require external technical assistance or financial resources.
- Data collectors require knowledge of the pharmaceutical sector and supply chain.
- The data is usually supplied by the stakeholders who hold public or private sector information.
Link to the tool: www.medicinestransparency.org/resources/meta-resources/meta-toolkits/
Country Experience: The Data Disclosure Survey has been undertaken in all seven MeTA pilot countries. Country reports are downloadable as PDFs:
